Four workers red-flagged in a 2014 review of SA’s troubled child protection agency remain suspended on full pay.

Informa Connect's Copay, Reimbursement and Access Congress
November 18-20, 2024 | Hilton Penn’s Landing in Philadelphia, PA
Drug Channels readers save 10% with code USAVE24*

The access and affordability landscape is undergoing a seismic shift. Evolving legislation, disruptive market forces and the ever-growing complexities of cost sharing programs threaten patient adherence and commercialization strategies. Are you ready?

A program driven by marketplace insights and led by industry trailblazers, Copay, Reimbursement and Access Congress is back November 18-20 and will deliver up-to-date insights necessary to enhance patient affordability, ensure program sustainability and navigate the regulatory landscape. In a time where remaining compliant has never been more complex and program innovation has never been more important, be sure to join your industry counterparts to drive adherence, access and commercialization forward.

Why attend the Copay, Reimbursement and Access Congress?

Keeping up with shifting market dynamics in the midst of maximizing access, while also meeting business objectives is a challenging task and brings about many questions for access professionals.

• Is your program sustainable and innovative to better support patients?
• Accumulators, maximizers, AFPs – What are your next steps to ensure effective reimbursement strategies?
• In an election year, what is the future of health policy?

Experts will tackle these questions and more as the industry comes together to benchmark best practices to accelerate access and commercialization. Do not miss your chance to join seasoned leaders, your peers and leading solution providers as they navigate marketplace trends and dive into the impact coupons, benefit design, accumulators, maximizers, alternative funding programs and drug pricing legislation have on patient affordability and out-of-pocket costs. This is your chance to gain critical insights on industry standards, forward-thinking strategies to optimize your copay and cost sharing programs and so much more.

Content highlights:

• Over 20 hours of content, including 7+ dedicated sessions to help decipher copay legislation
• Crucial perspectives from Pfizer, Sanofi, Janssen, Teva, Ascendis Pharma, Melinta Therapeutics, GSK, HIV + Hepatitis Policy Institute and more
• Insights direct from enforcement agents on the top trends and actions within the copay and patient services space
• Illuminating case study, Navigating the Patient Journey in a Shifting Copay Landscape from Spark Therapeutics
• 465 minutes of valuable in-person networking with colleagues and counterparts to expand your network and establish powerful partnerships
• Additional content access through Streamly, a platform that gives you 12-month access to all of the available conference content** to review at your leisure
• And more!

Download the agenda and register today—Be sure to use your exclusive promo USAVE24 to save 10% off* of your registration

See you there!

*Cannot be combined with other offers, promotions or applied to an existing registration. Other restrictions may apply.
**Pending speaker permissions

---

The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.

Last week, the Federal Trade Commission (FTC) released the redacted version of administrative complaint against the three largest pharmacy benefit managers (PBMs). The FTC rightly calls out how the gross-to-net bubble can raise patients’ out-of-pocket costs, while also acknowledging how rebates can reduce a plan's (but not the patient’s) costs. Apparently, the FTC believes that PBMs’ customers are pretty dumb, because PBMs are able to prevent plans from “appreciating” such healthcare financing dynamics.

Section V.E. of the complaint (starting on page 23) focuses on the PBMs’ alleged unlawful conduct related to preferring high-list/high-rebate insulin products over versions with lower list prices. I thought it would therefore be fun to take the Wayback Machine to November 2021, when I wrote about this specific topic.

Below, you can review my commentary about the warped incentives behind Viatris’ dual-pricing strategy for its interchangeable biosimilar of Lantus. Much of the FTC’s description of the drug channel aligns with my commentary. But before you fist pump too hard for Ms. Khan’s FTC, you should pause to reflect on the agency’s legal theories in light of plans’ revealed preferences.

---

The Food & Drug Administration (FDA) recently approved the first interchangeable biosimilar insulin product: the insulin glargine-yfgn injection from Viatris. Read the FDA’s press release.

Alas, I’m sad to report that the warped incentives baked into the U.S. drug channel will limit the impact of this impressive breakthrough.

Viatris is being forced to launch both a high-priced and a low-priced version of the biosimilar. However, only the high-list/high-rebate, branded version will be available on Express Scripts’ largest commercial formulary. Express Scripts will block both the branded reference product and the lower-priced, unbranded—but also interchangeable—version. Meanwhile, Prime Therapeutics will place both versions on its formularies, leaving the choice up to its plan sponsor clients.

Consequently, many commercial payers will adopt the more expensive product instead of the identical—but cheaper—version. As usual, patients will be the ultimate victims of our current drug pricing system.

Below, I explain the weird economics behind this decision, highlight the negative impact on patients, and speculate on what this all could mean for biosimilars’ future. Until plan sponsors break their addiction to rebates, today’s U.S. drug channel problems will remain.
Read more »

Eeek! It's time for Drug Channels’ Halloween roundup of terrifying tales to share with your ghoulish fiends. This month’s tricks and treats:

• Spooky! Blue Shield of California frightens away the gross-to-net bubble with its Humira biosimilar strategy

• Vampiric! Prior authorization sinks its fangs into providers’ time

• Wicked! How the IRA will put a stake through specialty physician practices

• Eerie! Google’s monstrous AI podcasts leave me petrified

• Zoinks! Join the vampire hunters at Drug Channels Institute

Plus, Dr. Glaucomflecken tells us a frightening tale of copayments.

P.S. Stretch out your arms and join the ever-growing zombie horde who shamble after me on LinkedIn. You’ll find my ghostly rantings along with commentary from the undead hordes in the DCI community.
Read more »

The Royal Pharmaceutical Society has expressed its sadness at the death of Joy Wingfield, honorary professor of Pharmacy Law and Ethics at the University of Nottingham.

Value-based care contracting is especially difficult for behavioral health providers, Taft Parsons III, chief psychiatric officer at CVS Health/Aetna, pointed out during a conference this week.

The post CVS Health Exec: Payers Need to Stop Making Behavioral Health Providers Jump Through Hoops In Order to Participate in Value-Based Care appeared first on MedCity News.

The Centers for Medicare and Medicaid Services (CMS) recently announced a 2.9% cut to Medicare physician payments for […]

The post CMS Cuts Medicare Physician Payments: What It Means appeared first on World of DTC Marketing.

Johnson & Johnson must pay US$15 million (S$19.6 million) to a Connecticut man who alleges that he developed mesothelioma, a rare form of cancer, as a result of using the company's talc powder for decades, a jury found on Tuesday (Oct 15). Plaintiff Evan Plotkin sued the company in 2021 soon after his diagnosis, saying he was sickened by inhaling J&J's baby powder. The jury in Fairfield County, Connecticut Superior Court also found that the company should pay additional punitive damages, which will be determined later by the judge overseeing the case. "Evan Plotkin and his trial team are thrilled that a jury once again decided to hold Johnson & Johnson accountable for their marketing and sale of a baby powder product that they knew contained asbestos," Ben Braly, a lawyer for Plotkin, said in an email. Erik Haas, J&J's worldwide vice president of litigation, said in a statement that the company would appeal "erroneous" rulings by the trial judge that kept the jury from hearing critical facts about the case.

South Korean actor Song Jae-rim died yesterday (Nov 12) at the age of 39. The Seongdong Police Station in Seoul confirmed that he was found deceased in his apartment at around 12.30pm. According to media reports, a friend whom he was supposed to meet for lunch had visited his home and reported the death. A two-page letter was reportedly found at the scene but the cause of death has not been confirmed. A police official, however, stated that there are "no signs of foul play". His wake was held at Yeouido St. Mary’s Hospital Funeral Hall at 5.30pm yesterday. His funeral will be held tomorrow at Seoul City Crematorium. Jae-rim gained popularity after starring in the 2012 drama The Moon Embracing the Sun and the 2014 reality series We Got Married. This year, he starred in two dramas — My Military Valentine and Queen Woo. Following news of his death, comedian Hong Seok-cheon and other celebrities posted tributes to Jae-rim on social media.

CrissCross Representative Payee Services

John Peden - #NMClientStory

Complete Tax Forms Fast, Easy, And Secure For Taxpayers And Accountants

Retailers Push for Greater Payment Security at Checkout to Combat Fraud and Cyber Theft

Fifth Third's eBus travels nationwide, armed with Fifth Third bankers to help customers in underbanked areas with all their financial needs, including budgeting tips, personal counseling and more.

BJ's Wholesale Club Members now have the option to �pick up and pay� at all of its 213 club locations along the east coast.

Healthcare leaders and the public say how they would balance the NHS� books

We are manufactured exporting company. We acquire godown , quareters from unregistered landlord on rent. Is this type of rent come under the applicability of RCM ?

I had bought a Pre-const house for 55lac and paid Stamp duty on 55lac during registration.
I made 54,00,00 payments in installments and now making the last installment of 1 lac

On the 26QB form

Total Value of Consideration (Property Value) -₹55,00,000
Payment type*-Installment
Whether it is last installment ?*-Yes
Whether stamp duty value is higher than sale consideration ?* - Dont know what to choose
Total amount paid/ credited in previous installments, if any (A) * ₹54,00,000
Amount paid/credited currently (B) *-₹1,00,000
Total stamp duty value of the property (C) *₹55,00,000

Now under
Tax Deposit Details, I am getting
Amount on which TDS to be deducted (D)*₹55,00,000, which looks wrong.

Should this not be the amount currently paid ₹1,00,000. What am I doing wrong?

Note*I was suggested in the forum to enter ₹1,00,000 in box (C), but it still calculates the total amount of ₹55,00,000 in (D)

We have taken registration number in central excise and want to pay service tax demand , however the code for that service is not available on the site then whether other duties code can be used or new registration is required??

IF WE FILE AN APPEAL AGAINST ORDER ISSUED UNDER SECTION 154, FOR PARTIAL ALLOW OF TDS AND LIABILITY TO PAY DEMAND IS MORE THAN 1,50,000 THEN IT IS MANDATORY TO PAY 20% OF DEMAND ISSUED UNDER SUCH RECTIFICATION ORDER?

Hi,
This question is w.r.t Final payment of TDS for property sale.
This is for 2 buyer and 1 seller.
Below is about 80% share of 1 seller.

Total Value of Consideration (Property Value) - 81,04,500 INR

Total amount paid/ credited in previous installments, if any (A) - 61,59,420 INR
Amount paid/credited currently (B) - 3,24,180 INR
Total stamp duty value of the property (C) - 64,83,600

Amount on which TDS to be deducted (D) is directly getting calculated at - 64,83,600 INR.

Ideally, since it is last installment, amount on which TDS to be deducted needs to be visible as 3,24,180 INR. However, it is showing 64,83,600.

Kindly help and update what needs to be filled in A, B & C so that I pay TDS of 1% on 3,24,180 INR only.

The Income Tax Department has intensified scrutiny on dubious tax refund claims for the assessment years 2021-22 and 2022-23, issuing notices to multiple taxpayers across the country. ...

Ross needed to write software to integrate with a credit card payment gateway. The one his company chose was relatively small, and only served a handful of countries- but it covered the markets they cared about and the transaction fees were cheap. They used XML for data interchange, and while they had no published schema document, they did have some handy-dandy sample code which let you parse their XML messages.

$response = curl_exec($ch);
$authecode = fetch_data($response, '<authCode>', '</authCode>');
$responsecode = fetch_data($response, '<responsecode>', '</responsecode>');
$retrunamount = fetch_data($response, '<returnamount>', '</returnamount>');
$trxnnumber = fetch_data($response, '<trxnnumber>', '</trxnnumber>');
$trxnstatus = fetch_data($response, '<trxnstatus>', '</trxnstatus>');
$trxnresponsemessage = fetch_data($response, '<trxnresponsemessage>', '</trxnresponsemessage>');

Well, this looks… worrying. At first glance, I wonder if we're going to have to kneel before Z̸̭͖͔͂̀ā̸̡͖͕͊l̴̜͕͋͌̕g̸͉̳͂͊ȯ̷͙͂̐. What exactly does fetch_data actually do?

function fetch_data($string, $start_tag, $end_tag)
{

  $position = stripos($string, $start_tag);
  $str = substr($string, $position);
  $str_second = substr($str, strlen($start_tag));
  $second_positon = stripos($str_second, $end_tag);
  $str_third = substr($str_second, 0, $second_positon);
  $fetch_data = trim($str_third);
  return $fetch_data;
}

Phew, no regular expressions, just… lots of substrings. This parses the XML document with no sense of the document's structure- it literally just searches for specific tags, grabs whatever is between them, and calls it done. Nested tags? Attributes? Self-closing tags? Forget about it. Since it doesn't enforce that your open and closing tags match, it also lets you grab arbitrary (and invalid) document fragments- fetch_data($response, "<fooTag>", "<barTag>"), for example.

And it's not like this needs to be implemented from scratch- PHP has built-in XML parsing classes. We could argue that by limiting ourselves to a subset of XML (which I can only hope this document does) and doing basic string parsing, we've built a much simpler approach, but I suspect that after doing a big pile of linear searches through the document, we're not really going to see any performance benefits from this version- and maintenance is going to be a nightmare, as it's so fragile and won't work for many very valid XML documents.

It's always amazing when TRWTF is neither PHP nor XML but… whatever this is.

Chain will still accept payments via JCB/American Express cards or other means

Full Article